MALE BREAST CANCER: RISK FACTORS, DIAGNOSIS AND TREATMENT

  2. 2026
  3. MALE BREAST CANCER: RISK FACTORS, DIAGNOSIS AND TREATMENT

Chornobay A. V.

MALE BREAST CANCER: RISK FACTORS, DIAGNOSIS AND TREATMENT

Show/Download

About the author:

Chornobay A. V.

Heading:

LITERATURE REVIEWS

Type of article:

Scientific article

Annotation:

The aim of the review is to study the incidence of breast cancer (BC) in men, the history of this pathology, and also to review the risk factors of diagnosis and treatment options, in particular adjuvant endocrine therapy. Foreign and domestic sources, as well as the results of several clinical studies, were analyzed. According to the latest NCCN clinical recommendations for the treatment of BC, an indication for genetic counseling is detected BC in men. At the 1st stage, mutations in the BRCA1 and BRCA2 genes are determined by the polymerase chain reaction method. Di agnosis of BC in men uses the same methods as in women. Given the relatively small number of cases, randomized controlled trials of BC treatment methods are extremely limited, and most recommendations are based on studies of breast cancer in women. Due to anatomical features, organ-preserving surgeries in men are practically not per formed (from 5 to 10%). Neoadjuvant therapy is carried out according to the same schemes as in women. Almost all studies indicate that in malignant tumors of the male breast the level of estrogen receptors is, on average, higher than in women. Clinically significant levels of estrogen receptors are found in more than 85% of breast tumors in men. Therefore, adequate treatment of BC is impossible without the use of endocrine adjuvant therapy. According to recent clinical studies, estrogen receptor blockers and gonadotropin-releasing hormone agonist analogues are preferred.

Tags:

endocrine therapy, male breast cancer, risk factors, treatment

Bibliography:

  1. Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010;28(12):2114.
  2. Yousef AJA. Male breast cancer: epidemiology and risk factors. Semin Oncol. 2017;44:267-72.
  3. Johansen Taber KA, Morisy LR, Osbahr AJ, Dickinson BD. Male breast cancer: risk factors, diagnosis, and management. Oncol Rep. 2010;24(5):1115-20.
  4. Mohamad HB, Apffelstaedt JP. Counseling for male BRCA mutation carriers – a review. Breast. 2008;17(5):441-50.
  5. Sasco AJ, Lowenfels AB, Jong PPD. Epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiolo-gical factors. Int J Cancer. 1993;53(4):538-49.
  6. Ferzoco RM, Ruddy KJ. The Epidemiology of Male Breast Cancer. Curr Oncol Rep. 2016;18(1):1.
  7. Ron E, Ikeda T, Preston DL, Tokuoka S. Male breast cancer incidence among atomic bomb survivors. J Natl Cancer Inst. 2005;97:603-5.
  8. Fentiman IS, Fourquet A, Horto-bagyi GN. Male breast cancer. Lancet. 2006;367(9510):595-604.
  9. Collins JM, Isaacs C. Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer. Breast J. 2020;26(8):1520-7.
  10. Fentiman IS. Male breast cancer is not congruent with the female disease. Crit Rev Oncol Hematol. 2016;101:119-124.
  11. Giordano SH. Breast cancer in men. N Engl J Med. 2018;378(24):2311-2320.
  12. Abrams MJ, Koffer PP, Wazer DE, Hepel JT. Postmastectomy radiation therapy is associated with improved survival in node-positive male breast cancer: a population analysis. Int J Radiat Oncol Biol Phys. 2017;98(2):384-391.
  13. Massarweh SA, Choi GL. Special considerations in the evaluation and management of breast cancer in men. Curr Problems Cancer. 2016;40(2-4):163-71.
  14. Speirs V, Shaaban AM. The rising incidence of male breast cancer. Breast Cancer Res Treat. 2009;115(2):429-430.
  15. Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, et al. Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Res Treat. 2019;173(1):37-48.
  16. Leon-Ferre RA, Giridhar KV, Hieken TJ, Mutter RW, Couch FJ, Jimenez RE, et al. A contemporary review of male breast cancer: current evidence and unanswered questions. Cancer Metastasis Rev. 2018;37(4):599-614.
  17. Jemal A, Lin CC, DeSantis C, Sineshaw H, Freedman RA. Temporal trends in and factors associated with contralateral prophylactic mas tectomy among US men with breast cancer. JAMA Surg. 2015;150(12):1192-1194.
  18. Wang F, Shu X, Meszoely I, Pal T, Mayer IA, Yu Z, et al. Overall Mortality After Diagnosis of Breast Cancer in Men vs Women. JAMA Oncol. 2019;5(11):1589-1596.
  19. Zaenger D, Rabatic BM, Dasher B, Mourad WF. Is breast conserving therapy a safe modality for early-stage male breast cancer? Clin Breast Cancer. 2016;16(2):101-104.
  20. Hassett MJ, Somerfield MR, Baker ER, Cardoso F, Kansal KJ, Kwait DC, et al. Management of male breast cancer: ASCO guideline. J Clin Oncol. 2020;38(16):1849-1863.
  21. Cutuli B, Le-Nir CC, Serin D, Kirova Y, Gaci Z, Lemanski C, et al. Male breast cancer. Evolution of treatment and prognostic factors. Anal ysis of 489 cases. Crit Rev Oncol Hematol. 2010;73(3):246-254.
  22. Takabe K. Breast-conserving surgery should not be recommended to men with early-stage breast cancer simply because we can perform these operations. HemOnc Today. 2016;17(12):13.
  23. Johansson I, Nilsson C, Berglund P, Strand C, Jonsson G, Staaf J, et al. High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer. Breast Cancer Res Treat. 2011;129(3):747-760.
  24. Port ER, Fey JV, Cody HS 3rd, Borgen PI. Sentinel lymph node biopsy in patients with male breast carcinoma. Cancer. 2001;91(2):319323.
  25. Eggemann H, Ignatov A, Stabenow R, von Minckwitz G, Rohl FW, Hass P, et sl. Male breast cancer: 20-year survival data for post-mas tectomy radiotherapy. Breast Care (Basel). 2013;8(4):270-275.
  26. Jardel P, Vignot S, Cutuli B, Creisson A, Vass S, Barranger E, et al. Should Adjuvant radiation therapy be systematically proposed for male breast cancer? A systematic review. Anticancer Res. 2018;38(1):23-31.
  27. Czene K, Bergqvist J, Hall P, Bergh J. How to treat male breast cancer. Breast. 2007;16(2): S147-154.
  28. Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst. 2007;99(5):365-375.
  29. Stebbing J, Baranau Y, Baryash V, Moiseyenko V, Boliukh D, Antone N, et al. Six-year Survival Outcomfor Patients with Her2- Positive Erly Breast Cancer Treated with CT-P6 or reference Trastuzumab: Observational Follow-up Stu of a Phase 32 Randomised controlled Trial. Bio Drags. 2023;37(3):433-440.
  30. Macari A, Soberanis-Pina P, Varela-Santoyo E, Valle-Sanchez MA, Leal-Hidalgo JL, Torres-Guillen VM, et al. Prevalence and molecular profile of breast carcinoma using immunohistochemistry markers in Mexican women. World J Oncol. 2021;12(4):119-123.
  31. Humphries MP, Sundara Rajan S, Honarpisheh H, Cserni G, Dent J, Fulford L, et al. Characterisation of male breast cancer: a descriptive biomarker study from a large patient series. Sci Rep. 2017;7:45293.
  32. Eggemann H, Brucker C, Schrauder M, Thill M, Flock F, Reinisch M, et al. Survival benefit of tamoxifen in male breast cancer: prospective cohort analysis. Br J Cancer. 2020;123(1):33-37.
  33. Corti C, Crimini E, Criscitiello C, Trapani D, Curigliano G. Adjuvant treatment of early male breast cancer. Curr Opin Oncol. 2020;32(6):594602.
  34. Zagouri F, Sergentanis TN, Koutoulidis V, Sparber C, Steger GG, Dubsky P, et al. Aromatase inhibitors with or without gonadotropin-releas ing hormone analogue in metastatic male breast cancer: a case series. Br J Cancer. 2013;108(11):2259-2263.
  35. Asaoka M, Gandhi S, Ishikawa T, Takabe K. Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future. Breast Cancer (Auckl). 2020;14:117.
  36. Kin T, Ohtani S, Maeda R, Ueno A, Fujihara M, Takamatsu Y, et al. Nab-paclitaxel followed by 5-fluorouracil, epirubicin and cyclophospha mide in neoadjuvant chemotherapy for resectable breast cancer: a phase ii trial. World J Oncol. 2020;11(5):197-203.
  37. Skrypnyk I, Masalova G, Lymanets T, Gusarenko I. L-arginine is an effective medication for prevention of endothelial dysfunction a predic tor of anthracycline cardiotoxicity in patient with acute leukemia. Exp Oncol. 2017:39(4):308-311
  38. Adeniji AA, Dawodu OO, Habeebu MY, Oyekan AO, Bashir MA, Martin MG, et al. Distribution of breast cancer subtypes among nigerian women and correlation to the risk factors and clinicopathological characteristics. World J Oncol. 2020;11(4):165-172.

Publication of the article:

«Bulletin of problems biology and medicine», 2026 Issue 1, 180, 151-161 pages, index UDC 618.19-006.6:615.849.19

DOI:

10.29254/2077-4214-2026-1-180-151-161

2026 Issue 1, 180
endocrine therapy male breast cancer risk factors treatment
29.03.2026
Was this article helpful?
0
0

Leave a Reply

Your email address will not be published. Required fields are marked *


The reCAPTCHA verification period has expired. Please reload the page.